Literature DB >> 2943927

Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.

C M Rooney, C D Gregory, M Rowe, S Finerty, C Edwards, H Rupani, A B Rickinson.   

Abstract

Tumor cells from 10 patients with Epstein-Barr virus-positive endemic Burkitt's lymphoma (BL) have been examined for cell surface phenotype, both at the biopsy stage and during BL cell line outgrowth in vitro, the cultures being followed for up to 150 passages. In all 10 cases, the biopsy cells showed coexpression of the common acute lymphoblastic leukemia antigen (CALLA) and of the BL-associated glycolipid antigen (BLA) with no accompanying expression of several "lymphoblastoid" cell surface markers defined by selected monoclonal antibodies. During cell line establishment and in vitro passage, the individual BL cell lines showed different degrees of progression toward a more "lymphoblastoid" cell surface phenotype, some even losing CALLA and BLA expression while retaining the chromosomal translocations indicative of their malignant origin. This differential capacity for phenotypic progression in vitro explains much, if not all, of the heterogeneity of the BL cell phenotype apparent from many previous studies with panels of long-established lines. Such heterogeneity in vitro belies the true homogeneity of the tumor cell phenotype in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2943927     DOI: 10.1093/jnci/77.3.681

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  29 in total

1.  Epstein-Barr virus nuclear antigen 5 inhibits pre-mRNA cleavage and polyadenylation.

Authors:  Martin Dufva; Josefine Flodin; Annika Nerstedt; Ulla Rüetschi; Lars Rymo
Journal:  Nucleic Acids Res       Date:  2002-05-15       Impact factor: 16.971

2.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  Impairment of natural killer functions by interleukin 6 increases lymphoblastoid cell tumorigenicity in athymic mice.

Authors:  J Tanner; G Tosato
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

4.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B.

Authors:  J R Arrand; L S Young; J D Tugwood
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

7.  Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.

Authors:  A B Rickinson; L S Young; M Rowe
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Distinctive patterns of histone H4 acetylation are associated with defined sequence elements within both heterochromatic and euchromatic regions of the human genome.

Authors:  C A Johnson; L P O'Neill; A Mitchell; B M Turner
Journal:  Nucleic Acids Res       Date:  1998-02-15       Impact factor: 16.971

9.  When Epstein-Barr virus persistently infects B-cell lines, it frequently integrates.

Authors:  E A Hurley; S Agger; J A McNeil; J B Lawrence; A Calendar; G Lenoir; D A Thorley-Lawson
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.

Authors:  S P Lee; W A Thomas; R J Murray; F Khanim; S Kaur; L S Young; M Rowe; M Kurilla; A B Rickinson
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.